CHRS
Price:
$1.24
Market Cap:
$142.86M
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biolo...[Read more]
Industry
Biotechnology
IPO Date
2014-11-06
Stock Exchange
NASDAQ
Ticker
CHRS
According to Coherus BioSciences, Inc.’s latest financial reports and current stock price. The company's current ROE is 23.81%. This represents a change of -341.19% compared to the average of -9.87% of the last 4 quarters.
The mean historical ROE of Coherus BioSciences, Inc. over the last ten years is 237.58%. The current 23.81% ROE has changed -89.98% with respect to the historical average. Over the past ten years (40 quarters), CHRS's ROE was at its highest in in the March 2018 quarter at 2.47%. The ROE was at its lowest in in the March 2022 quarter at -885.48%.
Average
237.58%
Median
66.22%
Minimum
-779.99%
Maximum
3.22%
Discovering the peaks and valleys of Coherus BioSciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 18.55%
Maximum Annual ROE = 3.22%
Minimum Annual Increase = -2568.62%
Minimum Annual ROE = -779.99%
Year | ROE | Change |
---|---|---|
2023 | 122.99% | -48.26% |
2022 | 237.69% | -175.83% |
2021 | -313.45% | -765.98% |
2020 | 47.07% | -44.88% |
2019 | 85.38% | -84.26% |
2018 | 542.46% | -169.55% |
2017 | -779.99% | 18.55% |
2016 | -657.94% | -120.42% |
2015 | 3.22% | -2568.62% |
2014 | -130.52% | -203.14% |
The current ROE of Coherus BioSciences, Inc. (CHRS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
15.74%
5-year avg
35.94%
10-year avg
237.58%
Coherus BioSciences, Inc.’s ROE is greater than Assembly Biosciences, Inc. (-121.55%), less than Spero Therapeutics, Inc. (20.70%), greater than Achilles Therapeutics plc (-47.36%), greater than Instil Bio, Inc. (-55.57%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than NextCure, Inc. (-57.63%), greater than Nuvation Bio Inc. (-98.79%), greater than CytomX Therapeutics, Inc. (-27.44%), greater than Bolt Biotherapeutics, Inc. (-61.40%), greater than Gracell Biotechnologies Inc. (-37.20%),
Company | ROE | Market cap |
---|---|---|
-121.55% | $107.81M | |
20.70% | $71.07M | |
-47.36% | $29.58M | |
-55.57% | $92.68M | |
-47.64% | $8.20M | |
-57.63% | $39.73M | |
-98.79% | $692.60M | |
-27.44% | $93.74M | |
-61.40% | $24.78M | |
-37.20% | $989.87M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Coherus BioSciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Coherus BioSciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Coherus BioSciences, Inc.'s ROE?
How is the ROE calculated for Coherus BioSciences, Inc. (CHRS)?
What is the highest ROE for Coherus BioSciences, Inc. (CHRS)?
What is the 3-year average ROE for Coherus BioSciences, Inc. (CHRS)?
What is the 5-year average ROE for Coherus BioSciences, Inc. (CHRS)?
How does the current ROE for Coherus BioSciences, Inc. (CHRS) compare to its historical average?